MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
+$0.05 today
- Market cap
- $129.06M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
Volume 0.97M
Average 0.95M
MXCT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
MaxCyte, Inc.NASDAQ: MXCT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.05M fell 18.0% year over year, behind the -11.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 18.6% from the prior quarter. Over 3 fiscal years it compounded at +24.0% a year.
Context
- Depreciation & amortization amounted to 15.6% of revenue in FY2025, up 3.2 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -18.0% toward the trailing-twelve-month pace of -11.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 5.14M USD
- Year-over-year change
- +7.3%
- 4-year CAGR
- +37.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.14M | +7.3% |
| FY2024 | 2024-12-31 | 4.79M | +14.8% |
| FY2023 | 2023-12-31 | 4.17M | +54.6% |
| FY2022 | 2022-12-31 | 2.7M | +89.5% |
| FY2021 | 2021-12-31 | 1.42M | — |
Depreciation & Amortization vs competitors
How MXCT compares with its peers on the latest reported figures
- MXCT's LTM Mar 2026 depreciation & amortization of $4.48M is the 4th highest of the 11 companies compared; the peer median is $2.67M.
- Its year-over-year change of -11.7% is the 7th highest of 11, against a peer median of +4.2%.
- Depreciation & amortization amounts to 13.9% of revenue for MXCT, versus a peer median of 13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $6.56M | -25.2% | -14.4% | 19.0% | |
| LTM Mar 2026 | $4.56M | +11.6% | +9.7% | 7.9% | |
| LTM Mar 2026 | $4.48M | -11.7% | +24.0% | 13.9% | |
| LTM Mar 2026 | $3.97M | +79.9% | -20.6% | 3.5% | |
| LTM Mar 2026 | $3.65M | +35.4% | +111.4% | 589.8% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.69M | +8.7% | +29.0% | 91.1% |
| LTM Mar 2026 | $1.61M | +16.3% | +19.7% | 54.5% | |
| LTM Mar 2026 | $627K | -41.1% | -39.6% | 0.6% | |
| LTM Mar 2026 | $589K | -20.5% | +14.8% | 1.3% | |
| LTM Mar 2026 | $499.7K | -57.0% | -29.2% | 2.6% | |
| Peer median (excluding MXCT) | $2.67M | +4.2% | +5.1% | 13.4% | |
Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.89M | 44.26M | 41.29M | 38.63M | 33.03M |
| Cost of Revenue | 3.65M | 5.1M | 4.74M | 7.1M | 6.22M |
| Gross Profit | 30.25M | 39.16M | 36.55M | 31.53M | 26.8M |
| Gross Margin | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| Research & Development | 15.41M | 19.51M | 23.82M | 22.23M | 20.82M |
| Selling, General & Admin | 31.68M | 44.48M | 57.04M | 56.35M | 47.04M |
| Operating Expenses | 48.44M | 66.52M | 84.85M | 82.72M | 72.09M |
| Depreciation & Amortization | 1.42M | 2.7M | 4.17M | 4.79M | 5.14M |
| EBITDA | (16.61M) | (20.75M) | (33.75M) | (36.27M) | (39.49M) |
| EBITDA Margin | -49.0% | -46.9% | -81.7% | -93.9% | -119.6% |
| Operating Income | (18.19M) | (27.36M) | (48.3M) | (51.2M) | (45.29M) |
| Operating Margin | -53.7% | -61.8% | -117.0% | -132.5% | -137.1% |
| Interest Income | 150.8K | 3.92M | 10.38M | 10.14M | 7.27M |
| Interest Expense | 1.04M | 126.9K | 0 | 0 | 0 |
| Other Income / Expenses | (893.6K) | 3.79M | 10.38M | 10.14M | 655K |
| Income Before Tax | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Pre-Tax Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Net Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| EPS (Basic) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| EPS (Diluted) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| Weighted Avg Shares | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
| Weighted Avg Shares (Diluted) | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
MaxCyte, Inc.
NASDAQ:MXCT
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.